<DOC>
	<DOCNO>NCT01470456</DOCNO>
	<brief_summary>Primary Objective : Participants Achieving Objective Response Rate ( Cheson 2007 ) Secondary Objectives : - Progression Free Survival - Overall Survival - Response Duration</brief_summary>
	<brief_title>Combination SAR3419 Rituximab Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>- The screening period = 4 week prior first administration combine therapy - The treatment period = 3 month combine therapy . A safety follow-up 42 49 day last dose treatment plan patient . - The follow-up period : Patients progress end study treatment follow progression initiation another anti-lymphoma therapy . All patient follow two year evaluate survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Inclusion criterion : Histological diagnosis Diffuse Large BCell Lymphoma ( DLBCL ) Relapsed refractory least one standard treatment include rituximab CD19 CD20 positive disease Exclusion criterion : No bidimensionally measurable lesion CT scan ( define presence least one tumor mass measure &gt; 1.5 x 1.5 cm ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>